Express News | Boston Scientific Corp : Jefferies Raises Target Price to $100 From $90
Boston Scientific Corp (BSX) Q3 2024 Earnings Call Highlights: Robust Growth and Strategic ...
Boston Scientific Pauses Enrollment In Farapulse Study In Drug-Naive Patients With Irregular Heart Rhythm
Needham Maintains Boston Scientific(BSX.US) With Hold Rating
Needham Sticks to Their Hold Rating for Boston Scientific (BSX)
Wall Street Slumps For Third Straight Day As Investor Sentiment Fades, Dollar Strength Resumes, Boeing Disappoints: What's Driving Markets Wednesday?
Sector Update: Health Care Stocks Retreat in Afternoon Trading
Boston Scientific's Strong Growth Trajectory Justifies Buy Rating Amid Strategic Advances
Boston Scientific Profit Falls Even as Demand for Its Heart Products Surges
Boston Scientific Raises Full-Year Guidance After Third-Quarter Beat
Citigroup Adjusts Boston Scientific's Price Target to $98 From $92, Keeps Buy Rating
Boston Scientific Faces Trial Setback, But This Game-Changing Growth Surge Could Ignite the Stock
BSX Q3 Earnings Top, Stock Down in Premarket as Operating Margin Falls
Boston Scientific Corporation (BSX) Q3 2024 Earnings Call Transcript Summary
Express News | Boston Scientific has raised its annual profit forecast and suspended heart device research.
Behind the Scenes of Boston Scientific's Latest Options Trends
Calculating The Intrinsic Value Of Boston Scientific Corporation (NYSE:BSX)
Boston Sci Stock Falls 4% Amid FARAPULSE Study Update
Boston Scientific Down Over 5%, on Pace for Largest Percent Decrease Since October 2023 -- Data Talk
Compared to Estimates, Boston Scientific (BSX) Q3 Earnings: A Look at Key Metrics